Arbutus Biopharma (ABUS) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 7.0% versus a loss of 4.3%. Over five years, ABUS leads with a +4.7% price change compared with -70.2% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($676.3 million vs $646.8 million), about 1.0 times the size, while Arbutus Biopharma is growing revenue faster (+128.2% vs +60.2%).
Lexicon Pharmaceuticals converts more of its revenue into profit, with a net margin of -101.1% versus -237.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | LXRX |
|---|---|---|
| Share price | $4.22 | $1.52 |
| Market cap | $646.82M | $676.33M |
| 1-day change | -1.63% | -7.88% |
| YTD return | -12.27% | +32.17% |
| 1-year return | -4.31% | +7.04% |
| 5-year return | +4.71% | -70.20% |
| P/E ratio (TTM) | 5.34 | — |
| EPS (TTM) | $0.79 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | $49.80M |
| Revenue growth (YoY) | +128.21% | +60.24% |
| Net income (latest FY) | $-33.50M | $-50.34M |
| Gross margin | — | 99.45% |
| Operating margin | -270.96% | -98.21% |
| Net margin | -237.88% | -101.08% |
| 52-week high | $5.45 | $2.68 |
| 52-week low | $3.50 | $1.10 |
| Distance from 52-week high | -22.57% | -43.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +27.96% | +199.34% |
| Average volume | 4.81M | 2.84M |
| Shares outstanding | 153.28M | 444.96M |
| Employees | 19 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed ABUS by 11.4 percentage points over the past year.
- Lexicon Pharmaceuticals is more profitable, keeping -101.1 cents of every revenue dollar as net income versus -237.9 cents for Arbutus Biopharma.
- Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs +60.24%).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
ABUS vs LXRX FAQ
Which is bigger, Arbutus Biopharma or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $676.33M compared with $646.82M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or LXRX?
LXRX returned +7.04% over the past 12 months, compared with -4.31% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.